Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine in Advanced HCC
NCT00464295Phase 2Completed
- Sponsor
- Aga Khan University
- Start
- Aug 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in hepatocellular carcinoma (HCC), sponsored by Aga Khan University. Primary endpoints: Response Rate at 12 months and Overall Survival at 12 months. Started Aug 2006; status: completed.
02
Drugs
capecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00464295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00464295.